BASF Pharma Solutions

pharma.basf.com

BASF creates chemistry for a sustainable future offering intelligent solutions to the pharmaceutical industry. With its expertise in polymer chemistry, R&D-capabilities and its commitment in developing excipients, BASF creates solutions for Instant & Modified Release, Solubilization, Softgels, Skin-Delivery and Biologics. BASF is the leading supplier of selected APIs such as ibuprofen and omega-3.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

RECRO ANNOUNCES ACQUISITION OF SAN DIEGO-BASED IRISYS, CREATING BI-COASTAL, FULL SERVICE CDMO

Recro Pharma, Inc. | August 16, 2021

news image

Recro Pharma, Inc. a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro. Recro acquired IRISYS for approximately $50 million in a combination of cash, shares of Recro common stock and a seller promissory note. With its acquisition of IRI...

Read More

Pharma Tech

THERORNA COMPLETES SERIES A FINANCING TO ACCELERATE PIPELINE DEVELOPMENT AND CLINICAL TRANSFORMATION OF CIRCRNA-BASED PLATFORM

Therorna Inc. | June 21, 2022

news image

Therorna Inc., a China-based biotech company specialized in the development of cutting-edge circular RNA technology-based new vaccines and therapies, announced the completion of a US$42 million Series A financing round. The round was co-led by a well-known industrial investment firm and MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital, demonstrating their continuous commitment to supporting Therorna'...

Read More

Business Insights, PHARMACY MARKET

HARROW INTRODUCES NEXT-GEN COMPOUNDED ATROPINE FORMULATIONS

Harrow | February 16, 2023

news image

On February 15, 2023, Harrow, a renowned pharmaceutical firm specializing in eyecare in the United States, announced the launch of its next-generation, patent-pending compounded Atropine formulations. These formulations are now accessible through ImprimisRx, a mail-order pharmacy subsidiary wholly owned by Harrow. The following are the key features of ImprimisRx's next-generation Atropine formulations Thoroughly validated analytical tests are conducted to...

Read More

Business Insights

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

news image

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More
news image

Business Insights

RECRO ANNOUNCES ACQUISITION OF SAN DIEGO-BASED IRISYS, CREATING BI-COASTAL, FULL SERVICE CDMO

Recro Pharma, Inc. | August 16, 2021

Recro Pharma, Inc. a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced its acquisition of IRISYS, a San Diego-based CDMO that possesses capabilities that complement and expand those of Recro. Recro acquired IRISYS for approximately $50 million in a combination of cash, shares of Recro common stock and a seller promissory note. With its acquisition of IRI...

Read More
news image

Pharma Tech

THERORNA COMPLETES SERIES A FINANCING TO ACCELERATE PIPELINE DEVELOPMENT AND CLINICAL TRANSFORMATION OF CIRCRNA-BASED PLATFORM

Therorna Inc. | June 21, 2022

Therorna Inc., a China-based biotech company specialized in the development of cutting-edge circular RNA technology-based new vaccines and therapies, announced the completion of a US$42 million Series A financing round. The round was co-led by a well-known industrial investment firm and MSA Capital, with participation from Sherpa Healthcare Partners, 3H Health Investment, and existing investors Quan Capital and Cenova Capital, demonstrating their continuous commitment to supporting Therorna'...

Read More
news image

Business Insights, PHARMACY MARKET

HARROW INTRODUCES NEXT-GEN COMPOUNDED ATROPINE FORMULATIONS

Harrow | February 16, 2023

On February 15, 2023, Harrow, a renowned pharmaceutical firm specializing in eyecare in the United States, announced the launch of its next-generation, patent-pending compounded Atropine formulations. These formulations are now accessible through ImprimisRx, a mail-order pharmacy subsidiary wholly owned by Harrow. The following are the key features of ImprimisRx's next-generation Atropine formulations Thoroughly validated analytical tests are conducted to...

Read More
news image

Business Insights

VIFOR PHARMA DRIVES TRANSFORMATION WITH DIVESTMENT OF NON-CORE FINISHED DRUG MANUFACTURING TO CORDENPHARMA

Vifor Pharma Group | December 17, 2021

Vifor Pharma Group announced the divestment of its finished drug product manufacturing business to CordenPharma, a full-service Contract Development & Manufacturing Organization of APIs, Excipients, Drug Products, and associated Packaging services. This decision reinforces Vifor Pharma’s strategy to transform the company into a multi-brand commercial organization, focusing on its core capabilities in-licensing, partnering and commercializing products in nephrology, and to further grow ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us